Seventy-six percent of 65 psychotherapy cases seen in a child guidance clinic either did not chan... more Seventy-six percent of 65 psychotherapy cases seen in a child guidance clinic either did not change or improved following a mandated report of suspected child abuse. In a significant minority of cases, the therapy relationship deteriorated when the report was made about a client in treatment, and improved when the report was made about a third party not in treatment.
Thymidine phosphorylase (TP) metabolizes the final step in the conversion of capecitabine to 5-fl... more Thymidine phosphorylase (TP) metabolizes the final step in the conversion of capecitabine to 5-fluorouracil. Taxanes increase the expression of TP, and the combination of docetaxel and capecitabine is synergistic in human xenograft models. 1,2 Based on preclinical observations and a previous phase I trial, 3 a randomized trial of docetaxel (75 mg/m 2 on day 1) and capecitabine (1250 mg/m 2 twice daily on days 1-14, repeated every 21 days) versus docetaxel alone (100 mg/m 2 ) demonstrated statistically significantly superior response rates, time to progression (TTP), and overall survival in favor of the combination in patients with metastatic breast cancer (MBC) pretreated with anthracyclines. 4 Subsequently, the regimen was approved by the Food and Drug Administration and is used widely in clinical practice.
Seventy-six percent of 65 psychotherapy cases seen in a child guidance clinic either did not chan... more Seventy-six percent of 65 psychotherapy cases seen in a child guidance clinic either did not change or improved following a mandated report of suspected child abuse. In a significant minority of cases, the therapy relationship deteriorated when the report was made about a client in treatment, and improved when the report was made about a third party not in treatment.
Thymidine phosphorylase (TP) metabolizes the final step in the conversion of capecitabine to 5-fl... more Thymidine phosphorylase (TP) metabolizes the final step in the conversion of capecitabine to 5-fluorouracil. Taxanes increase the expression of TP, and the combination of docetaxel and capecitabine is synergistic in human xenograft models. 1,2 Based on preclinical observations and a previous phase I trial, 3 a randomized trial of docetaxel (75 mg/m 2 on day 1) and capecitabine (1250 mg/m 2 twice daily on days 1-14, repeated every 21 days) versus docetaxel alone (100 mg/m 2 ) demonstrated statistically significantly superior response rates, time to progression (TTP), and overall survival in favor of the combination in patients with metastatic breast cancer (MBC) pretreated with anthracyclines. 4 Subsequently, the regimen was approved by the Food and Drug Administration and is used widely in clinical practice.
Uploads
Papers by Holly Watson